Zai Lab Picks ENPICOM's IGX Platform to Use New NGS-powered...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Zai Lab Picks ENPICOM's IGX Platform to Use New NGS-powered Antibody Discovery Workflows

Pharma Tech Outlook | Friday, June 04, 2021

Jos Lunenberg, Founder and Chief Executive Officer, ENPICOM

Zai Lab plans to use Next Generation Sequencing (NGS) as a supplement to their antibody selection process.

FREMONT, CA: ENPICOM, an innovative bioinformatics software engineering firm, announced that Zai Lab Limited, an innovative, research-based, commercial-stage biopharmaceutical corporation based in China and the U.S., has signed a subscription agreement for ENPICOMs IGX Platform. The Antibody Discovery Module (ADM) of the IGX Platform is a software platform that helps researchers diversify and improve their candidate pools by picking genetic sequences related to a set of desirable therapeutic features from a database of millions of such sequences. Zai Lab plans to use Next Generation Sequencing (NGS) as a supplement to their antibody selection process.

“Zai Lab is a leader in innovative drug discovery and development in China, conducting many discovery, preclinical, and clinical programs around the world. We are delighted to provide them with the IGX Platform to optimize their antibody discovery workflow and to accelerate the development of innovative drugs,” said Jos Lunenberg, co-founder and Chief Executive Officer, ENPICOM.

With integrated bulk NGS, single-cell sequencing, and Sanger data processing, targeted and efficient candidate selection is possible. A more specific and simplified selection of antibodies to express and test in the lab is made possible by the efficient analysis of NGS data. As a result, candidate pools are more diverse, and applicants with better traits are identified.The analysis of Sanger and NGS data together for antibody discovery needs

specialized software that provides:

• Capabilities for bulk NGS raw data quality control;

• Flexible and comprehensive metadata annotation possibilities; robust data management abilities;

• Analysis of high-level repertoire characteristics to evaluate the immunological competency of diverse animal models;

• A user-friendly solution for guided cluster selection, sequence clustering, and phylogenetic analysis;

• Integrated bulk NGS, single cell, and Sanger data analyses for optimal antibody candidate selection;

• ENPICOM’s IGX Platform with ADM satisfies these requirements and provides a flexible method for expanding and diversifying the candidate pool and more effectively selecting better antibodies.

  •  

Weekly Brief

Read Also